689291-66-5Relevant articles and documents
In vitro studies on a class of quinoline containing histamine H3 antagonists
Liu, Huaqing,Altenbach, Robert J.,Diaz, Gilbert J.,Manelli, Arlene M.,Martin, Ruth L.,Miller, Thomas R.,Esbenshade, Timothy A.,Brioni, Jorge D.,Cowart, Marlon D.
scheme or table, p. 3295 - 3300 (2010/08/07)
A series of quinoline containing histamine H3 antagonists is reported herein. These analogs were synthesized via the Friedlander quinoline synthesis between an aminoaldehyde intermediate and a methyl ketone allowing for a wide diversity of subs
Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists
Altenbach, Robert J.,Liu, Huaqing,Banfor, Patricia N.,Browman, Kaitlin E.,Fox, Gerard B.,Fryer, Ryan M.,Komater, Victoria A.,Krueger, Kathleen M.,Marsh, Kennan,Miller, Thomas R.,Jia, Bao Pan,Pan, Liping,Sun, Minghua,Thiffault, Christine,Wetter, Jill,Zhao, Chen,Zhou, Deliang,Esbenshade, Timothy A.,Hancock, Arthur A.,Cowart, Marlon D.
, p. 5439 - 5448 (2008/03/13)
A new structural series of histamine H3 receptor antagonist was developed. The new compounds are based on a quinoline core, appended with a required basic aminoethyl moiety, and with potency- and property-modulating heterocyclic substituents. The analogs
Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
-
Page/Page column 32, (2010/02/14)
Compounds of formula (I) wherein R1 or R2 is a tricyclic or bicyclic ring, each of which contains at least two heteroatoms, and R1, R2, R3, R3a, R3b, R4, R5, L, X, X′, Y, Y′, Z, and Z′ are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
